Xiuhua Lu

Xiuhua Lu

Auto-generated profile, based on publicly available information

Xiuhua Lu

Department of Pharmaceutical, Linyi Central Hospital, Yishui, Shandong, China

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2014 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
ZLZhu-Nan Li
Zhu-Nan Li
SLSeh-Ching Lin
Seh-Ching Lin
PCPaul J. Carney
Paul J. Carney
JLJi Li
Ji Li
FLFeng Liu
Feng Liu
KHKathy Hancock
Kathy Hancock
The novel influenza A(H1N1)pdm09 virus caused an influenza pandemic in 2009. IgM, IgG, and IgA antibody responses to A(H1N1)pdm09 hemagglutinin (HA) following A(H1N1)pdm09 virus infection were analyzed to understand antibody isotype responses. Age-matched control sera collected from U.S. residents in 2007 and 2008 were used to establish baseline levels of cross-reactive antibodies. IgM responses often used as indicators of primary virus infection were mainly detected in young patient groups (≤5 years and 6 to 15 years old), not in older age groups, despite the genetic and antigenic differences between the HA of A(H1N1)pdm09 virus and pre-2009 seasonal H1N1 viruses. IgG and IgA responses to A(H1N1)pdm09 HA were detected in all age groups of infected persons. In persons 17 to 80 years old, paired acute- and convalescent-phase serum samples demonstrated ≥4-fold increases in the IgG and IgA responses to A(H1N1)pdm09 HA in 80% and 67% of A(H1N1)pdm09 virus-infected persons, respectively. The IgG antibody response to A(H1N1)pdm09 HA was cross-reactive with HAs from H1, H3, H5, and H13 subtypes, suggesting that infections with subtypes other than A(H1N1)pdm09 might result in false positives by enzyme-linked immunosorbent assay (ELISA). Lower sensitivity compared to hemagglutination inhibition and microneutralization assays and the detection of cross-reactive antibodies against homologous and heterologous subtype are major drawbacks for the application of ELISA in influenza serologic studies.

29 June 2021 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
XLXiuhua Lu
Xiuhua Lu
SYShibin Yan
Shibin Yan
KKKelly Ann Koral
Kelly Ann Koral
ZCZhongguang Chen
Zhongguang Chen
Introduction: Surufatinib (also known as HMPL-012, sulfatinib) is a novel oral tyrosine kinase inhibitor (TKI), which has the dual activity of anti-angiogenesis and immune regulation. In December 2020, surufatinib was approved as a monotherapy for unresectable locally advanced or metastatic, progressive nonfunctioning, well differentiated (grade 1 or 2) extrapancreatic neuroendocrine tumors (epNETs) in China. Areas covered: In this paper, the chemical properties, mechanism of action, pharmacokinetics, clinical efficacy, safety, and tolerability of surufatinib for treatment of advanced extrapancreatic NETs are introduced in detail. We performed a systematic review of the literature in PubMed and the following keywords were used: ‘surufatinib,’ ‘sulfatinib’ and ‘HMPL-012.’ Expert opinion: Surufatinib is a potent, selective, and small-molecule TKI that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor 1 (FGFR1) and colony stimulating factor 1 receptor (CSF1R). Surufatinib showed an acceptable safety profile and encouraging antitumor activity in patients with advanced epNETs. The most frequently observed adverse events (AEs) were hypertension and proteinuria. Surufatinib provides a new treatment option for patients with advanced epNETs. More clinical trials of surufatinib are ongoing to develop a combination of therapy strategies and new indications for malignancies.

30 August 2022 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
JGJunfa Gao
Junfa Gao
JLJunsheng Li
Junsheng Li
XLXiuhua Lu
Xiuhua Lu
JYJunyi Yang
Junyi Yang
Olanzapine (OLZ) is one of the most effective antipsychotic agents, however, its clinical utility has been limited by weight gain. Samidorphan (SAM) is aμ-opioid receptor antagonist and it can redu...

1 June 2004 in International Congress Series
Verified
Journal Article
Closed access
JDJ.A Desheva
J.A Desheva
LRLarisa G. Rudenko
Larisa G. Rudenko
GAG.I Alexandrova
G.I Alexandrova
XLX Lu
X Lu
ARAndrey Rekstin
Andrey Rekstin
AKA.I Klimov
A.I Klimov